Ponesimod, also known as ACT-128800, is a potent, and orally active selective S1P(1) agonist. Ponesimod activated S1P(1)-mediated signal transduction with high potency (EC(50) of 5.7 nM) and selectivity. Ponesimod prevented edema formation, inflammatory cell accumulation, and cytokine release in the skin of mice with delayed-type hypersensitivity. Ponesimod also prevented the increase in paw volume and joint inflammation in rats with adjuvant-induced arthritis. Ponesimod may represent a new therapeutic approach in lymphocyte-mediated autoimmune diseases.

 

Brand: BCM

 

Boiling Point: 658.0±65.0 °C(Predicted)

 

pKa: 13.38±0.20(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water.

 

InChi Key: LPAUOXUZGSBGDU-STDDISTJSA-N

 

Attribute
[Chem Name]	(Z)-5-((Z)-3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one
[Synonym]	ACT-128800; ACT 128800; ACT128800; Ponesimod
[CAS No.]	854107-55-4
[MDL No.]	MFCD18207776
[Formula]	C23H25ClN2O4S
[Molecular]	460.97
[Form]	Solid powder

Goods Tag